Market Access The companies shaping the UK’s commercial landscape Which companies are working with the government to implement the US-UK pharmaceutical trade agreement?
Market Access Highlights from the UK’s December 2025 VPAG metrics Leela Barham looked at the latest metrics used to monitor the UK’s voluntary pricing scheme.
News NHS braces for thousands of redundancies UK Health Secretary Wes Streeting has given the green light to a series of NHS reforms that will see around 18,000 administrative roles abolished.
Market Access Progress with the UK’s VPAG Leela Barham looks at the first operational review meeting minutes that have been published on the VPAG, the UK’s latest scheme on branded medicines pricing and access, building on previous
Market Access Metrics for the UK’s VPAG: A work in progress Just as for previous schemes, metrics are being used to track VPAG, the UK’s voluntary scheme that covers branded medicines pricing and access.
Market Access How transparent is the VPAG? Leela Barham takes a look at the transparency of the UK’s new pricing and access scheme, the 2024 VPAG, based on public sources.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
R&D Sponsored The future of cardiometabolic trials: From obesity to outcom... Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO
